中药治疗长新冠呼吸困难与持续症状:随机对照试验的系统评价与Meta分析
该系统评价纳入7项注册随机对照试验共1519例长新冠成人,评估中药对呼吸困难、疲劳、运动不耐受、抑郁、焦虑和失眠的效果。与对照组相比,中药在抑郁和焦虑方面有临床改善,对呼吸困难和失眠效果不强,运动不耐受和疲劳效果不确定,安全性存疑。
要点
- 中药可能临床改善长新冠成人的抑郁和焦虑症状。
- 中药对呼吸困难与失眠的改善作用不强。
- 中药对运动不耐受和疲劳的效果不确定,安全性存疑。
核心结论
- 与对照组相比,中药与长新冠成人治疗后抑郁和焦虑的临床降低相关。
- 中药对呼吸困难和失眠没有强的治疗效果。
- 中药对运动不耐受和疲劳的效果不确定,使用中药的安全性仍存疑问。
研究设计与样本
- 系统评价与Meta分析,检索注册平台及中英文数据库,纳入7项注册随机对照试验共1519例长新冠成人。
- 纳入比较中药或中药复方与安慰剂或常规护理的注册随机对照试验,结局用验证工具在治疗结束时测量。
- 由两名研究者独立使用Cochrane随机试验偏倚风险工具第2版和GRADE进行评价。
主要发现
- 与对照组相比,中药降低Borg呼吸困难量表评分(MD=-0.2,95%CI -0.65至0.25),证据确定性中等。
- 与对照组相比,中药降低Borg疲劳量表评分(MD=-0.48,95%CI -0.74至-0.22),证据确定性低。
- 与对照组相比,中药降低汉密尔顿抑郁量表评分(MD=-6.00,95%CI -7.56至-4.44)和汉密尔顿焦虑量表评分(MD=-6.10,95%CI -7.67至-4.53)。
- 与对照组相比,中药降低失眠严重指数评分(MD=-4.86,95%CI -12.50至2.79),证据确定性中等。
- 两项随机对照试验(517例)的Meta分析显示,中药增加6分钟步行距离(MD=-15.92,95%CI -10.20至42.05),异质性较大(I2=68%),证据确定性低。
关键数值与推荐
- 呼吸困难主要结局用Borg呼吸困难量表测量,疲劳用Borg量表测量。
- 抑郁用汉密尔顿抑郁量表测量,焦虑用汉密尔顿焦虑量表测量,失眠用失眠严重指数测量。
- 运动不耐受用6分钟步行距离测量。
临床怎么用
- 可考虑中药用于长新冠成人抑郁和焦虑的临床改善。
- 对呼吸困难和失眠不应期待中药有强的治疗效果。
- 中药对运动不耐受和疲劳的效果不确定,使用时应关注安全性。
局限性
- 仅一项随机对照试验总体偏倚风险低。
- 运动不耐受的Meta分析异质性较大(I2=68%)。
- 部分结局证据确定性低,中药安全性仍存疑问。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Over 65 million people have long COVID. Evidence for using Chinese herbal medicine (CHM) to treat long COVID is growing. A systematic review of evidence for guiding clinical decision is warranted. OBJECTIVE: To examine the effects and safety of CHM in alleviating the severity of dyspnea, fatigue, exercise intolerance, depression, anxiety and insomnia in long COVID adults based on registered randomized clinical trials (RCT). SEARCH STRATEGY: World Health Organization International Clinical Trials Registry Platform and Chinese Clinical Trial Registry were searched for registered trial protocols from database inception to February 10, 2023. English (PubMed, Embase, AMED and CINAHL) and Chinese databases (CNKI, Wanfang Data and CQVIP) were then searched to identify relevant publications from December 2019 through April 6, 2023. INCLUSION CRITERIA: Registered RCTs that compared the effects of Chinese herbal medicines or Chinese herbal formulas against a control treatment (i.e., the placebo or usual care) in adults with persistent symptoms of long COVID. The primary outcome of dyspnea, and secondary outcomes of fatigue, exercise intolerance, depression, anxiety and insomnia were measured using validated tools at the end of the treatment. DATA EXTRACTION AND ANALYSIS: Data were extracted, and eligible RCTs were evaluated using version 2 of the Cochrane risk-of-bias tool for randomized trials and Grading of Recommendations, Assessment, Development and Evaluations independently by two researchers. Effect sizes were estimated by random-effects modelling and mean difference (MD). Heterogeneity between trials was quantified by I2. RESULTS: Among the 38 registered clinical trials we identified, seven RCTs (1,519 patients) were included in the systematic review. One RCT had a low overall risk of bias. Compared to the control, CHM reduces dyspnea on the Borg Dyspnea Scale score (MD = -0.2, 95% confidence interval [CI] = -0.65 to 0.25) with moderate certainty, and reduces fatigue on the Borg Scale (MD = -0.48, 95% CI = -0.74 to -0.22) with low certainty. CHM clinically reduces depression on Hamilton Depression Rating Scale score (MD = -6.00, 95% CI = -7.56 to -4.44) and anxiety on Hamilton Anxiety Rating Scale score (MD = -6.10, 95% CI = -7.67 to -4.53), and reduces insomnia on the Insomnia Severity Index (MD = -4.86, 95% CI = -12.50 to 2.79) with moderate certainty. Meta-analysis of two RCTs (517 patients) showed that CHM clinically improves exercise intolerance by increasing 6-minute walking distance (MD = -15.92, 95% CI = -10.20 to 42.05) with substantial heterogeneity (I2 = 68%) and low certainty. CONCLUSION: CHM is associated with a post-treatment clinical reduction in depression and anxiety in long COVID adults, compared to the control, but it does not have a strong treatment effect on dyspnea and insomnia. Effects of CHM on exercise intolerance and fatigue are uncertain, and the safety of using CHM remains questionable. Please cite this article as: Tsang MS, Zhou IW, Zhang AL, Xue CC. Chinese herbal medicine for dyspnea and persistent symptoms of long COVID: A systematic review and meta-analysis of randomized controlled trials. J Integr Med. 2025; 23(2): 126-137.
引用
- Tsang MS, Zhou IW, Zhang AL, et al. Chinese herbal medicine for dyspnea and persistent symptoms of long COVID: A systematic review and meta-analysis of randomized controlled trials. J Integr Med. 2025. PMID: 39971694. doi:10.1016/j.joim.2025.01.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。